AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
According to a study from the United States, "Whereas chemotherapy is the standard of care for metastatic castration-resistant prostate cancer and is associated with a survival benefit, there remains a need for alternative approaches. Extensive work has been done evaluating multiple immunotherapies for the treatment of prostate cancer."
"This review discusses clinical results for the most promising developments. These include cytokine-based therapy with GM-CSF; vaccines; antibody-based immunotherapies, including anti-cytotoxic T lymphocyte associated antigen 4 therapy and antibodies against additional targets; and dendritic cell-based immunotherapy," wrote A.L. Harzstark and colleagues, University of California (see also Cancer Vaccines).
The researchers concluded: "The Oncologist 2009; 14:391-398'."
Harzstark and colleagues published the results of their research in Oncologist (Immunotherapeutics in Development for Prostate Cancer. ...